Domestic listing status and purchasing methods of voclosporin

Voclosporin (Voclosporin) is currently not on the market in China, so domestic patients cannot directly obtain the drug through formal channels. Due to the lack of time to market and medical insurance inclusion information, the domestic price, reimbursement policy and drug purchase process have not yet been clarified. If patients consider using it, they need to wait for formal approval or obtain it through clinical trial channels.

In overseas markets, Voclosporin has received marketing approval for the treatment of kidney diseases related to systemic lupus erythematosus (SLE). Taking the European version as an example, each box with a specification of 7.9mg*180 capsules is priced at about 16,000 yuan. It is relatively expensive and is mainly intended for patients with specific diseases and for clinical research purposes. Exchange rates and regional differences may cause actual selling prices to fluctuate.

At present, there are no generic drugs of Voclosporin in overseas markets. Therefore, if patients choose to purchase drugs overseas, they can only obtain them through formal channels of original drugs, such as prescriptions from overseas hospitals or approval of imported drugs. When purchasing, you need to pay attention to the legality of drug sources, storage conditions and transportation safety, and avoid using drugs from informal channels to ensure drug safety.

Overall, Voclosporin is still unmarketed in China, and its access is limited. Patients should evaluate their own indications and treatment necessity under the guidance of a doctor, and pay attention to domestic marketing trends and medical insurance policies. If you need to purchase medicines overseas, you should choose legal channels and prepare cost budgets and drug management to ensure the safety and effectiveness of treatment.